Abstract
HTS is at the core of the drug discovery process, and so it is critical to design and implement HTS assays in a comprehensive fashion involving scientists from the disciplines of biology, chemistry, engineering, and informatics. This requires careful analysis of many variables, starting with the choice of assay target and ending with the discovery of lead compounds. At every step in this process, there are decisions to be made that can greatly impact the outcome of the HTS effort, to the point of making it a success or a failure. Although specific guidelines should be established to ensure that the screening assay reaches an acceptable level of quality, many choices require pragmatism and the ability to compromise opposing forces.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AAO:
-
automated assay optimization
- AAS:
-
atomic absorbance spectroscopy
- BRET:
-
bioluminescence resonance energy transfer
- Bicine:
-
N,N-bis(2-Hydroxyethyl)glycine
- Bmax:
-
maximum binding capacity
- BSA:
-
bovine serum albumin
- CHAPS:
-
3-([3-Cholamidopropyl]dimethylammonio)-1-propanesulfonate
- CV:
-
coefficient of variation
- DMSO:
-
dimethyl sulfoxide
- DTT:
-
dithiothreitol
- ECL:
-
electrochemiluminescence
- EDTA:
-
ethylenediamine-N,N,N′,N′-tetraacetic acid
- EFC:
-
enzyme fragment complementation
- EGTA:
-
ethylene glycol-bis(2-aminoethyl)-N,N,N′,N′-tetraacetic acid
- ELISA:
-
Enzyme-linked immunosorbent assay
- FCS:
-
fluorescence correlation spectroscopy
- FIDA:
-
fluorescence intensity distribution analysis
- FLINT:
-
fluorescence intensity
- FRET:
-
fluorescence resonance energy transfer
- FP:
-
fluorescence polarization
- GPCR:
-
G protein-coupled receptor
- HTS:
-
high-throughput screening
- Kd:
-
dissociation constant
- L:
-
ligand
- M:
-
mean
- NSB:
-
non specific binding
- OD:
-
optical density unit
- PEI:
-
polyethylene imine
- PMSF:
-
phenylmethylsulfonyl fluoride
- RIA:
-
Radioimmunoassay
- S/B:
-
signal to background ratio
- S/N:
-
signal to noise ratio
- SD:
-
standard deviation
- SW:
-
signal window
- SPA:
-
scintillation proximity assay
- TAPS:
-
N-tris (Hydroxymethyl)methyl-3-aminopropanesulfonic acid
- TR-FRET:
-
time-resolved fluorescence resonance energy transfer
- Vmax:
-
maximum velocity
References
Cascieri MA, Springer MS. (2000) The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention. Curr Opin Chem Biol; 4:420–427.
Miller WH, Alberts DP, Bhatnagar PK et al. (2000) Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem; 43:22–26.
Fox S. (2007) Throughput Screening 2007: New Strategies, Success Rates, and Use of Enabling Technologies (HighTech Business Decisions Market report: http://www.hightechdecisions.com/reports.html).
Macarrón R. (2006) Critical review of the role of HTS in drug discovery. Drug Discov Today; 11:277–279.
Gonzalez JE, Oades K, Leychkis Y, Harootunian A, Negulescu PA. (1999) Cell-based assays and instrumentation for screening ion-channel targets. Drug Discov Today; 4:431–439.
Schroeder KS, Neagle BD. (1996) FLIPR: A new instrument for accurate, high throughput optical screening. J Biomol Screen; 1:75–80.
Shoichet BK. (2006) Screening in a spirit haunted world. Drug Discov Today; 11:607–615.
Inglese J, Johnson RL, Simeonov A et al. (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol; 3:466–479.
Eggeling C, Brand L, Ullmann D, Jäger S. (2003) Highly sensitive fluorescence detection technology currently available for high throughput screening. Drug Discov Today; 8:632–641.
Pope AJ, Haupts U, Moore KJ. (1999) Homogeneous fluorescence readouts for miniaturized high-throughput screening; Theory and practice. Drug Discov Today; 4:350–362.
Gaudet EA, Huang KS, Zhang Y, Huang W, Mark D, Sportsman JR. (2001) A homogeneous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. J Biomol Screen; 8:164–175.
Wu S, Liu B. (2005) Application of scintillation proximity assay in drug discovery. Biodrugs; 19:383–392.
Glickman J, Wu X, Mercuri R et al. (2002) A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors. J Biomol Screen; 7:3–10.
Debad JD, Glezer EN, Wohlstadter JN, Sigal GB. (2004) Clinical and biological applications of ECL. In: Bard AJ (ed.), Electrogenerated Chemiluminescence. New York: Marcel Dekker, pp. 43–78.
Rich RL, Myszka DG. (2007) Higher-throughput, label-free, real-time molecular interaction analysis. Anal Biochem; 361:1–6.
Gabriel D, Vernier M, Pfeifer MJ, Dasen B, Tenaillon L, Bouhelal R. (2003) High throughput screening technologies for direct cyclic AMP measurement. Assay Drug Dev Technol; 1:291–303.
Zheng W, Spencer R, Kiss L. (2004) High throughput assay technologies for ion channel drug discovery. Assay Drug Dev Technol; 2:543–552.
Terstappen GC. (2005) Ion channel screening technologies today. Drug Discov Today: Technol; 2:133–140.
Hill SJ, Baker JG, Rees S. (2001) Reporter-gene systems for the study of G-protein-coupled receptors. Curr Opin Pharmacol; 1:526–532.
Fan F, Wood KV. (2007) Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol; 5:127–136.
Poulsen F, Jensen KB. (2007) A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma. J Biomol Screen; 12:240–247.
Assay Guidance Manual Version 4.1. Eli Lilly and Company and NIH Chemical Genomics Center (2005) (Accessed December 14, 2007, at http://www.ncgc.nih.gov/guidance/manual_toc.html.).
Cheng YC, Prussof W. (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol; 22:3099–3108.
Bush K. (1983) Screening and characterization of enzyme inhibitors as drug candidates. Drug Metab Reviews; 14:689–708.
Macarron R, Mensah L, Cid C et al. (2000) A homogeneous method to measure aminoacyl-tRNA synthetase aminoacylation activity using scintillation proximity assay technology. Anal Biochem; 284:183–190.
Tipton KF. (1980) Kinetics and enzyme inhibition studies. In: Sandler M (ed.), Enzyme Inhibitors as Drugs. Baltimore: University Park Press, pp. 1–23.
Burt D. (1986) Receptor binding methodology and analysis. In: O'Brien RA (ed.), Receptor Binding in Drug Research. New York: Decker, pp. 4–29.
Gupta S, Indelicato S, Jethwa V et al. (2007) Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods; 321:1–18.
Kost TA, Condreay JP, Ames RS, Rees S, Romanos MA. (2007) Implementation of BacMam virus gene delivery technology in a drug discovery setting. Drug Discov Today; 12:396–403.
Lundholt B, Scudder K, Pagliaro L. (2003) A simple technique for reducing edge effect in cell-based assays. J Biomol Screen; 8:566–570.
Lutz MW, Menius JA, Choi TD et al. (1996) Experimental design for high-throughput screening. Drug Discov Today; 1:277–286.
Taylor P, Stewart F, Dunnington DJ et al. (2000) Automated Assay Optimization with Integrated Statistics and Smart Robotics. J Biomol Screen; 5:213–225.
Zhang JH, Chung TDY, Oldenburg KR. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen; 4:67–73.
Iversen PW, Eastwood BJ, Sittampalam GS, Cox KL. (2006) A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio. J Biomol Screen; 11:247–252.
Barnett V. (1974) Elements of Sampling Theory. London: The English Universities Press, pp. 42–46.
Acknowledgments
The authors are grateful to the many colleagues at GlaxoSmithKline, which helped over the years to shape the screening process and to build the collective knowledge succinctly described in this introduction.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Macarrón, R., Hertzberg, R.P. (2009). Design and Implementation of High-Throughput Screening Assays. In: Janzen, W., Bernasconi, P. (eds) High Throughput Screening. Methods in Molecular Biology, vol 565. Humana Press. https://doi.org/10.1007/978-1-60327-258-2_1
Download citation
DOI: https://doi.org/10.1007/978-1-60327-258-2_1
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-257-5
Online ISBN: 978-1-60327-258-2
eBook Packages: Springer Protocols